Hidradenitis Suppurativa (HS): Current and Emerging Treatments
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".
Deadline for manuscript submissions: closed (20 February 2024) | Viewed by 3574
Special Issue Editor
Interests: dermatology; hidradenitis; psoriasis; biologic drugs; dermoscopy; ultrasonography; teledermatology; melanoma; skin tumors; basal cell carcinoma; wound care; inflammatory skin disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hidradenitis suppurativa (HS) to date remains a difficult disease for the dermatologist to manage due to gaps in knowledge about its etiology. There are few therapeutic choices for the treatment of HS. To date, the only FDA-approved drug remains Adalimumab (antiTNFa).
However, recent studies on the pathogenesis of HS have made it possible to investigate new therapies. Thanks to the many clinical trials currently underway in the future, it is hoped that therapeutic choices can be expanded.
This Special Issue, entitled “Hidradenitis Suppurativa: Current and Emerging Therapies”, aims to bring together articles in which new therapies that specifically target cytokines involved in the pathogenesis of HS can be discussed. We hope that this Special Issue will expand the knowledge on this disease and invite colleagues to report their experiences.
Dr. Claudio Marasca
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hidradenitis Suppurativa
- treatment
- adalimumab
- secukinumab
- guselkumab
- biologic therapies
- small molecules
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.